Cargando…

Convergent synthesis and evaluation of (18)F-labeled azulenic COX2 probes for cancer imaging

The overall objectives of this research are to (i) develop azulene-based positron emission tomography (PET) probes and (ii) image COX2 as a potential biomarker of breast cancer. Several lines of research have demonstrated that COX2 is overexpressed in breast cancer and that its presence correlates w...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolting, Donald D., Nickels, Michael, Tantawy, Mohammed N., Yu, James Y. H., Xie, Jingping, Peterson, Todd E., Crews, Brenda C., Marnett, Larry, Gore, John C., Pham, Wellington
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539664/
https://www.ncbi.nlm.nih.gov/pubmed/23316477
http://dx.doi.org/10.3389/fonc.2012.00207
_version_ 1782255131952152576
author Nolting, Donald D.
Nickels, Michael
Tantawy, Mohammed N.
Yu, James Y. H.
Xie, Jingping
Peterson, Todd E.
Crews, Brenda C.
Marnett, Larry
Gore, John C.
Pham, Wellington
author_facet Nolting, Donald D.
Nickels, Michael
Tantawy, Mohammed N.
Yu, James Y. H.
Xie, Jingping
Peterson, Todd E.
Crews, Brenda C.
Marnett, Larry
Gore, John C.
Pham, Wellington
author_sort Nolting, Donald D.
collection PubMed
description The overall objectives of this research are to (i) develop azulene-based positron emission tomography (PET) probes and (ii) image COX2 as a potential biomarker of breast cancer. Several lines of research have demonstrated that COX2 is overexpressed in breast cancer and that its presence correlates with poor prognoses. While other studies have reported that COX2 inhibition can be modulated and used beneficially as a chemopreventive strategy in cancer, no viable mechanism for achieving that approach has yet been developed. This shortfall could be circumvented through in vivo imaging of COX2 activity, particularly using sensitive imaging techniques such as PET. Toward that goal, our laboratory focuses on the development of novel (18)F-labled COX2 probes. We began the synthesis of the probes by transforming tropolone into a lactone, which was subjected to an [8 + 2] cycloaddition reaction to yield 2-methylazulene as the core ring of the probe. After exploring numerous synthetic routes, the final target molecule and precursor PET compounds were prepared successfully using convergent synthesis. Conventional (18)F labeling methods caused precursor decomposition, which prompted us to hypothesize that the acidic protons of the methylene moiety between the azulene and thiazole rings were readily abstracted by a strong base such as potassium carbonate. Ultimately, this caused the precursors to disintegrate. This observation was supported after successfully using an (18)F labeling strategy that employed a much milder phosphate buffer. The (18)F-labeled COX2 probe was tested in a breast cancer xenograft mouse model. The data obtained via successive whole-body PET/CT scans indicated probe accumulation and retention in the tumor. Overall, the probe was stable in vivo and no defluorination was observed. A biodistribution study and Western blot analysis corroborate with the imaging data. In conclusion, this novel COX2 PET probe was shown to be a promising agent for cancer imaging and deserves further investigation.
format Online
Article
Text
id pubmed-3539664
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-35396642013-01-11 Convergent synthesis and evaluation of (18)F-labeled azulenic COX2 probes for cancer imaging Nolting, Donald D. Nickels, Michael Tantawy, Mohammed N. Yu, James Y. H. Xie, Jingping Peterson, Todd E. Crews, Brenda C. Marnett, Larry Gore, John C. Pham, Wellington Front Oncol Oncology The overall objectives of this research are to (i) develop azulene-based positron emission tomography (PET) probes and (ii) image COX2 as a potential biomarker of breast cancer. Several lines of research have demonstrated that COX2 is overexpressed in breast cancer and that its presence correlates with poor prognoses. While other studies have reported that COX2 inhibition can be modulated and used beneficially as a chemopreventive strategy in cancer, no viable mechanism for achieving that approach has yet been developed. This shortfall could be circumvented through in vivo imaging of COX2 activity, particularly using sensitive imaging techniques such as PET. Toward that goal, our laboratory focuses on the development of novel (18)F-labled COX2 probes. We began the synthesis of the probes by transforming tropolone into a lactone, which was subjected to an [8 + 2] cycloaddition reaction to yield 2-methylazulene as the core ring of the probe. After exploring numerous synthetic routes, the final target molecule and precursor PET compounds were prepared successfully using convergent synthesis. Conventional (18)F labeling methods caused precursor decomposition, which prompted us to hypothesize that the acidic protons of the methylene moiety between the azulene and thiazole rings were readily abstracted by a strong base such as potassium carbonate. Ultimately, this caused the precursors to disintegrate. This observation was supported after successfully using an (18)F labeling strategy that employed a much milder phosphate buffer. The (18)F-labeled COX2 probe was tested in a breast cancer xenograft mouse model. The data obtained via successive whole-body PET/CT scans indicated probe accumulation and retention in the tumor. Overall, the probe was stable in vivo and no defluorination was observed. A biodistribution study and Western blot analysis corroborate with the imaging data. In conclusion, this novel COX2 PET probe was shown to be a promising agent for cancer imaging and deserves further investigation. Frontiers Media S.A. 2013-01-03 /pmc/articles/PMC3539664/ /pubmed/23316477 http://dx.doi.org/10.3389/fonc.2012.00207 Text en Copyright © Nolting, Nickels, Tantawy, Yu, Xie, Peterson, Crews, Marnett, Gore and Pham. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
spellingShingle Oncology
Nolting, Donald D.
Nickels, Michael
Tantawy, Mohammed N.
Yu, James Y. H.
Xie, Jingping
Peterson, Todd E.
Crews, Brenda C.
Marnett, Larry
Gore, John C.
Pham, Wellington
Convergent synthesis and evaluation of (18)F-labeled azulenic COX2 probes for cancer imaging
title Convergent synthesis and evaluation of (18)F-labeled azulenic COX2 probes for cancer imaging
title_full Convergent synthesis and evaluation of (18)F-labeled azulenic COX2 probes for cancer imaging
title_fullStr Convergent synthesis and evaluation of (18)F-labeled azulenic COX2 probes for cancer imaging
title_full_unstemmed Convergent synthesis and evaluation of (18)F-labeled azulenic COX2 probes for cancer imaging
title_short Convergent synthesis and evaluation of (18)F-labeled azulenic COX2 probes for cancer imaging
title_sort convergent synthesis and evaluation of (18)f-labeled azulenic cox2 probes for cancer imaging
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539664/
https://www.ncbi.nlm.nih.gov/pubmed/23316477
http://dx.doi.org/10.3389/fonc.2012.00207
work_keys_str_mv AT noltingdonaldd convergentsynthesisandevaluationof18flabeledazuleniccox2probesforcancerimaging
AT nickelsmichael convergentsynthesisandevaluationof18flabeledazuleniccox2probesforcancerimaging
AT tantawymohammedn convergentsynthesisandevaluationof18flabeledazuleniccox2probesforcancerimaging
AT yujamesyh convergentsynthesisandevaluationof18flabeledazuleniccox2probesforcancerimaging
AT xiejingping convergentsynthesisandevaluationof18flabeledazuleniccox2probesforcancerimaging
AT petersontodde convergentsynthesisandevaluationof18flabeledazuleniccox2probesforcancerimaging
AT crewsbrendac convergentsynthesisandevaluationof18flabeledazuleniccox2probesforcancerimaging
AT marnettlarry convergentsynthesisandevaluationof18flabeledazuleniccox2probesforcancerimaging
AT gorejohnc convergentsynthesisandevaluationof18flabeledazuleniccox2probesforcancerimaging
AT phamwellington convergentsynthesisandevaluationof18flabeledazuleniccox2probesforcancerimaging